List of Excipients in Branded Drug SOHONOS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ipsen Biopharmaceuticals Inc	SOHONOS	palovarotene	15054-0010	CELLULOSE, MICROCRYSTALLINE	2030-08-16
Ipsen Biopharmaceuticals Inc	SOHONOS	palovarotene	15054-0010	CROSCARMELLOSE SODIUM	2030-08-16
Ipsen Biopharmaceuticals Inc	SOHONOS	palovarotene	15054-0010	FERROSOFERRIC OXIDE	2030-08-16

Excipient Strategy and Commercial Opportunities for SOHONOS (Sojonos/sohonos?) in US Market

Last updated: July 30, 2026

SOHONOS has a defined, high-scrutiny formulation and manufacturing path tied to its active pharmaceutical ingredient and finished dosage form. Commercial opportunities for new entrants and manufacturers cluster around (1) FDA regulatory positioning via formulation and manufacturing changes that avoid infringement of existing Orange Book-listed patents, (2) differentiated excipient systems that improve stability, wetting, dissolution, and dose uniformity, and (3) supply-chain resilience via alternative processing and packaging strategies that reduce risk of batch failures.

Important note on scope: The requested excipient strategy must map to SOHONOS’s specific excipient list, dosage form, and the patent landscape covering formulation and manufacturing. That requires exact FDA labeling (inactive ingredients and dosage form) and Orange Book patent records for SOHONOS. Without those data, an accurate, infringement-aware excipient and commercial opportunity analysis cannot be produced.

If sufficient information is not available, no complete and accurate response is possible.